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Abstract
ChemProt is a publicly available compilation of chemical-protein-disease annotation re-
sources that enables the study of systems pharmacology for a small molecule across
multiple layers of complexity from molecular to clinical levels. In this third version,
ChemProt has been updated to more than 1.7 million compounds with 7.8 million bio-
activity measurements for 19 504 proteins. Here, we report the implementation of global
pharmacological heatmap, supporting a user-friendly navigation of chemogenomics
space. This facilitates the visualization and selection of chemicals that share similar struc-
tural properties. In addition, the user has the possibility to search by compound, target,
pathway, disease and clinical effect. Genetic variations associated to target proteins
were integrated, making it possible to plan pharmacogenetic studies and to suggest
human response variability to drug. Finally, Quantitative Structure–Activity Relationship
models for 850 proteins having sufficient data were implemented, enabling secondary
pharmacological profiling predictions from molecular structure.
Database URL: http://potentia.cbs.dtu.dk/ChemProt/
Introduction
Many chemical biology initiatives in Europe and the USA
aim to screen large compound collections with dedicated
bioassays i.e. EU Lead Factory (1), EU-Openscreen (2) or
BARD in the USA (3). Such large initiatives generate large
amounts of data that support academic and industrial
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research in the discovery of safer chemicals, with better ef-
ficacy. To make chemical biology information accessible to
scientists, several repositories of bioactive small molecules
have been developed: ChEMBL (4), PubChem (5),
ChemSpider (6) and OpenPhacts (7) are the largest, more
general databases available to the public. The National
Institutes of Health’s Molecular Libraries Program (MLP)
funding developed the BioAssay Research Database
(BARD), focusing on assay ontologies for PubChem bio-
assays (3).
Advances in chemical biology and systems biology
have shown that most drugs interact with multiple targets
and that the pharmacological profile of a drug is not as re-
ductionist as once believed (8). Moreover, proteins rarely
operate in isolation within and outside cells but function
in interconnected pathways instead. Given the integration
afforded by systems biology, it is now possible to consider
a more general physiological environment for protein tar-
gets and biological processes. As massive amounts of data
are generated and accumulated via new experimental
technologies such as transcriptomic, proteomics and gen-
omics (through next-generation sequencing), drug action
can be explored across multiple scale of complexity, from
molecular and cellular to tissue and organism levels (9–
11).
Multi-target pharmacology exploration increases when
information linking the relationship between chemical and
target spaces is readily available. As archived data are pro-
cessed and homogenized, our total knowledge on pro-
teinligand interactions is increasing at an amazing pace
(12, 13). Scientists having access to these data, approaches
such as chemogenomics, proteochemometrics and poly-
pharmacology have started to emerge (14, 15). These help
to mine evaluate and ultimately distil this vast amount of
protein–ligand interactions data, enabling the predictions
of single ligands against a set of heterogeneous targets
(16).
This third version of ChemProt is not a simple update
for disease chemical biology data. Rather, we provide a
friendly platform to navigate through the various data
sources, from global evaluations to a focused analysis.
Several computational approaches are included: ligand-
based similarity, target-based promiscuity, QSAR
(Quantitative Structure–Activity Relationship) method-
ology and network biology-based enrichment analyses.
These approaches support novel hypotheses generation for
bioactivity of novel and already-annotated compounds,
and the ability to identify additional genes that may play
major roles in modulating chemical perturbations in man.
The updates and new methods introduced in ChemProt-
3.0 are presented below.
Data sources
We updated all the chemical protein interactions data from
the open source databases ChEMBL (version 19) (4),
BindingDB (17), PDSP Ki database (18), DrugBank (ver-
sion 4) (19), PharmGKB (20), IUPHAR-DB database (21)
and STITCH (version 4) (22). Clinical information from
the Anatomical Therapeutic Chemical Classification
System (23) developed by the World Health Organization,
as well as side effect data from Sider 2 were also integrated
(24).
From a biological perspective, we updated our internal
human interactome platform to reach 14 421 genes inter-
acting through 507 142 unique PPIs (25). OMIM (26), the
human disease network (27) GeneCards (28), KEGG (29),
Reactome (30), UniPathway (31) and Gene Ontology (32)
databases were also downloaded, curated and included in
our system. Overall, the integrated data sources were
increased by over 60% compared to the earlier version.
As many different data types were aggregated in
ChemProt, a ‘zChemProt’ value for each compound-
bioactivity interactions was computed for visualization in
the several heatmaps developed. Basically, for each of the
11 most prevalent data types (IC50, EC50, Potency, AC50,
pIC50, Log Ki, pKi, pEC50, Kd, Ki), a zChemProt value was
computed using the mean and standard deviation calcu-
lated from the distribution of the associated data types for
each target in a similar way described in CARLSBAD data-
base (33). IC50, EC50, Potency, AC50, Kd and Ki were log
transformed before computing the zChemProt values.
Large values indicate strong chemical–protein interactions
and are represented in orange. Low value (weak inter-
actions) is depicted in blue.
Predictions methods
Daylight-like 1024 bit fingerprints was computed with
RDkit (www.rdkit.org) and the chemical similarity be-
tween two compounds was quantitatively assessed using
the Tanimoto coefficient (34). The Similarity Ensemble
Approach (SEA) (35) has been re-compiled on the
ChemProt server and updated according to the novel
zChemProt data and integrated into ChemProt 3.0. Only
proteins with >10 chemicals were included for SEA predic-
tion, using the same protocol as described in the previous
version (36). For sequence analyses, protein sequences
were obtained from Uniprot (37). Sequences comparisons
were computed using BLASTP and estimated to be similar
when their E value was lower than 1010 (38). All com-
pounds were decomposed into ring scaffolds based on an
internal implementation of the ‘Scaffold Hunter’













hierarchical classification algorithm (39–40) with the add-
ition of decomposition of non-ring molecule based on rules
7–10, as described by Schuffenhauer et al. (41). This hier-
archical decomposition allows the generation of scaffold
trees enabling an easy and interactive navigation of the
chemical biology space in large datasets and the identifica-
tion of potential new compound classes with desired
bioactivity.
For this release, QSAR models were trained for each
protein with >20 chemicals (in total 850 proteins). A
Naı¨ve Bayes classifier was trained using 5-fold cross-valid-
ation for performance assessment. Features selection, five
different computational fingerprints (Daylight and
Morgan fingerprints) and three different cutoffs (log 10
value: 4, 5 and 6) for classifying active and non-active
compounds, were used to produce overall 15 classification
models for each target. To predict new compound, each
model was weighted by the cross-validated performance
measure resulting in a prediction value between 0 and 1
(where 1 is high predicted binding). To avoid bias toward
negative or positive data, each of the three datasets used
for training were balanced by including as many negative
compounds as positive including random compounds from
the ChemProt database. The performance of the developed
QSAR ensemble approach was tested on a dataset of
hERG binders and showed an improved performance
compared to a previous reported study (42) (Aroc¼ 0.827,
Matthews Correlation Coefficient (MCC)¼ 0.488 using 5-
fold cross-validation). Furthermore, the method was
benchmarked against the SEA implementation on a dataset
consisting of 143 proteins with associated activity values
from the ChemProt-3.0 dataset. In a 5-fold cross-valid-
ation scheme on each of the 143 proteins, the QSAR mod-
els outperform SEA (Pval¼2.2e 16, paired t-test of
Spearman correlation coefficients for each protein predic-
tions). However, models developed from limited amounts
of data might not provide reliable predictions. The user
can consult the ‘prediction info’ tab (by clicking on the
protein of interest on the heatmap) to obtain the number
of molecules used for training the QSAR models. Details
about the procedure are described in Supplementary
Information.
Visual interface
In ChemProt 3.0, the front page was modified to have all
the functionality available on the page. The user has the
possibility to search information about a compound, a pro-
tein and a clinical outcome, or he can choose to perform a
QSAR prediction for a specific compound. A molecule can
be imported as a SMILES code, or alternatively it can be
drawn or uploaded from a compound structure file via the
SD file format. A new function called ‘Heatmap’ was inte-
grated, which allows the user to have a global view of
chemical-protein interactions (Figure 1). In this graphical
interface, the user has the possibility to localize the bio-
activity associated to a requested compound, a set of
defined compounds or a set of similar compounds based
on the chemical structure. Several layers of granularity
have been implemented on the heatmap. The proteins have
been categorizes by families, using the protein classifica-
tion tree implemented in ChEMBL and the compounds
have been decomposed in scaffold and chemical groups
based on the scaffold tree implementation similar to
CARLSBAD. This gives the user the opportunity to visual-
ize scaffold-protein activity relationships. A color spectrum
from blue (low activity) to orange (strong activity) is used
to indicate the activity. All compounds structures and pro-
tein IDs (based on Uniprot) are clickable, which gives ac-
cess to more detailed information about physicochemical
properties and protein function respectively.
An interesting feature with this graphical interface is the
possibility to match other biological to chemical data.
Instead of choosing ‘for drugs’, the user can select targets,
pathways, diseases or side effects and see the association
between chemicals and these endpoints.
From the protein ID, the user has access to the proteins
complex (represented as a protein’s network from protein–
protein interaction data). The complex of proteins is then
mapped to biological terms such as diseases, GO terms and
pathways with a corrected P value to evaluate the signifi-
cance of these associations.
Finally, the user has the possibility to download the
results in flat-file format to perform others analyses.
Methodology: Daylight-like fingerprints, defined by
1024 fragments were computed using RDkit (www.rdkit.
org). The QSAR models were trained using scikit-learn
software (http://scikit-learn.org/stable/). The visual inter-
face was implemented using HTML 5 and JavaScript. The
webserver is limited for an input file of 50 molecules (in
SMILES or sdf file) per query to limit the time necessary to
get the output. For larger queries, the user is advised to
contact us.
Applications
Caffeine, a well-known natural product extracted from
coffee beans or tea leaves, is often used as a central nervous
system stimulant (43). Several outputs can be displayed
like those shown in Figure 2. Typing the compound name
in the ‘Compound’ field and clicking on the Submit button,
the user is redirected to the global chemical-protein heat-
map with the query compound showing up in the com-
pound list as default. Any compound can be added to the













list by writing a new compound name in the ‘search’ box.
Clicking on the ‘flag’ next to a compound name in the
compound list prompts the heatmap to zoom in or out
from that specific compound, enabling a fast way to visual-
ize the proteins signature for the queried compound, as
well as for compounds sharing scaffold similarities.
Clicking on the ‘fingerprint’ logo in the vicinity of the
compound name, a chemical structure similarity profiling
can be performed, enabling the user to visualize and to
navigate within that pharmacological heatmap. For the
Caffeine example, 105 similar compounds (with a
Tanimoto coefficient> 0.85) were found, with bioactivities
associated to 449 proteins (from weak in blue to strong in
orange). The user is able to zoom in the heatmap and to
narrow the information from the classification proteins
tree to specific proteins (defined by uniprot ID). The user
has also the possibility to navigate inside the heatmap. One
option is to fill out missing values by choosing ‘SEA’ or
‘QSAR’ under prediction in the top of the page.
By clicking on the compound structure, physicochemi-
cal features [such as the Lipinski rules (44)], number of
proteins with bioactivities and the databases from which
the information was gathered, are shown. Similarly, the
user can click on a specific protein name and get more in-
formation on the function of the protein, diseases associ-
ated to this protein and predictions based on SEA and
QSAR. For example, under ‘family A GPCR’, caffeine is
shown to be potent (35.5 nM) on the rat muscarinic M1
acetylcholine receptor (P08482). It also shows a strong as-
sociation with the dopamine D2 receptor (P14416) based
on the STITCH system. By clicking on this protein, the
user is presented with information on this dopamine recep-
tor. Notably, disease associations are queried through the
TCRD (Target Central Ressource Database Application:
Figure 1. Global view of the chemical-protein interactions heatmap in ChemProt.













http://juniper.health.unm.edu/tcrd/) database and the gen-
etic variation through the Ensembl database (45). A com-
plex disease network is also associated to this protein.
Clicking on this link, diseases (such as schizophrenia and
epilepsy) and GO terms (plasma membrane, ligand-gated
ion channel activity, etc.) are shown.
Instead of looking for ‘functional’ protein annotation, it
is further possible to select ‘pathway’ or ‘diseases’ for
caffeine (also for the set of 105 similar compounds). The
heatmap will be depicted according to the query. Each
protein annotation (functional, pathway, disease) is pre-
sented in a tree format. Proteins have been categorized
from families to proteins using the protein target tree im-
plemented in ChEMBL. It has been done similarly for the
pathway using the unipathway (31) implementation tree
and disease using the human disease network (27). For ex-
ample, using the disease heatmap, strong associations are
found between caffeine and ventricular tachycardia, slow
acetylation, glycogen storage disease, dystonia and thyroid
carcinoma.
Finally, from the ChemProt-3 front page, the user can
write the caffeine’s SMILES in the QSAR prediction box,
click on ‘Submit QSAR’ and then get a prediction of posi-
tive and negative bioactivities for the ensemble of proteins
in ChemProt where reliable QSAR models can be pro-
duced. This option allows the user to have a direct QSAR
prediction for a new compound not present in the
ChemProt database.
Conclusion
Given that access to many chemogenomics databases is
possible, linking them to biological resources and using
a number of machine learning tools, scientists can now
estimate the bioactivity profile of molecules across a
large number of targets, pathways, diseases and other
clinical outcomes using ligand-based, target-based and
network-based models. Such multi-target, multi-layer
strategies are becoming more and more accepted by the
scientific community. Within ChemProt, it is possible to
Figure 2. Information that can be collected from a search on caffeine. Top left, functional information on bioactive proteins for the query compound is
depicted. Bottom left, chemical and physicochemical information is gathered. Top right, protein’s complex associated to the chemical is shown and
the bottom right is depicted the protein’s annotation and prediction (through QSAR) for caffeine.













navigate the chemogenomics space and to link chem-
ically induced target perturbations to diseases and other
biological outcomes. Such tools might be of interest for
drug discovery, drug safety and also chemical risk assess-
ment. ChemProt 3.0 supports predicting bioactivities on
targets and off-targets for new compounds and can assist
in the associations to phenotypes and side effects
relationships.
Supplementary Data
Supplementary data are available at Database Online.
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